Detection and identification of potential biomarkers of non-small cell lung cancer

Technology in Cancer Research and Treatment

Volumn 8, Issue 6, 2009, Pages 455-466

  Yang, Yang ^a   Zhao, Song ^b   Fan, Yuxia ^b   Zhao, Feng ^a   Liu, Quan ^a   Hu, Wei ^b   Liu, Donglei ^a   Fan, Kai ^a   Wang, Jiaxiang ^b   Wang, Jianjun ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Biomarker; LC MS MS; Non small cell lung cancer; Protemics; SELDI TOF MS

Indexed keywords

APOLIPOPROTEIN C1; BIOLOGICAL MARKER; HAPTOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MALE; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; UPREGULATION;

EID: 74049150760     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460900800607     Document Type: Article

References (32)

1. Youlden, D. R., Cramb, S. M., Baade, P. D. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 3, 819-831 (2008).
2. Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Pro 83, 584-594 (2008).
3. Mulshine, J. L., Sullivan, D. C. Clinical practice. Lung cancer screening. N Engl J Med 352, 2714-2720 (2005).
4. Gudbjartsson, T., Smáradottir, A., Skúladóttir, H., Grímsson, H. N., Hardardóttir, H., Bjornsson, J., Hannesson, P., Haraldsdóttir, S. O., Jónsson, S. Lung cancer-review. Laeknabladid 94, 297-311 (2008).
5. Schneider, J., Velcovsky, H. G., Morr, H., Katz, N., Neu, K., Eigenbrodt, E. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 20, 5053-5058 (2000).
6. Schneider, J., Bitterlich, N., Velcovsky, H. G., Morr, H., Katz, N., Eigenbrodt, E. Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol 7, 145-151 (2002).
7. Maurya, P., Meleady, P., Dowling, P., Clynes, M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res 27, 1247-1255 (2007).
8. Goncalves, A., Charafe-Jauffret, E., Bertucci, F., Audebert, S., Toiron, Y., Esterni, B., Monville, F., Tarpin, C., Jacquemier, J., Houvenaeqhel, G., Chabannon, C., Extra, J. M., Viens, P., Borg, J. P., Birnbaum, D. Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 7, 1420-1433 (2008).
9. Wang, J., Zhang, X., Ge, X., Guo, H., Xiong, G., Zhu, Y. Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol Oncol 111, 111-119 (2008).
10. Skytt, A., Thysell, E., Stattin, P., Stenman, U. H., Antti, H., Wikstrom, P. SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Int J Cancer 121, 615-620 (2007).
11. Liu, D., Cao, L., Yu, J., Que, R., Jiang, W., Zhou, Y., Zhu, L. Diagnosis of Pancreatic Adenocarcinoma Using Protein Chip Technology. Pancreatology 9, 127-135 (2008).
12. Looi, K. S., Nakayasu, E. S., Diaz, R. A., Tan, E. M., Almeida, I. C., Zhang, J. Y. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res 7, 4004-4012 (2008).
13. Hundt, S., Haug, U., Brenner, H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 16, 1935-1953 (2007).
14. Watanabe, Y. TNM classification for lung cancer. Ann Thorac Cardiovasc Surg 9, 343-350 (2003).
15. Vapnik, V., Chapelle, O. Bounds on error expectation for support vector machines. Neural Comput 12, 2013-2036 (2000).
16. Somorjai, R. L., Dolenko, B., Baumgartner, R. Class prediction and discovery using gene microarray and proteomics mass spectroscopy data: curses, caveats, cautions. Bioinformatics 19, 1484-1491 (2003).
17. Fang, J., Dong, Y., Williams, T. D., Lushington, G. H. Feature selection in validating mass spectrometry database search results. J Bioinform Comput Biol 6, 223-240 (2008).
18. Song, G., Ouyang, G., Bao, S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9, 59-71 (2005).
19. Wassell, J. Haptoglobin: function and polymorphism. Clin lab 46, 547-552 (2000).
20. Weinberg, E. D. The role of iron in cancer. Eur J Cancer Prev 5, 19-36 (1996).
21. Reizenstein, P. Iron, free radicals and cancer. Med Oncol Tumor Pharmacother 8, 229-233 (1991).
22. Saldova, R., Royle, L., Radcliffe, C. M., Abd Hamid, U. M., Evans, R., Arnold, J. N., Banks, R.E., Hutson, R., Harvey, D. J., Antrobus, R., Petrescu, S. M., Dwek, R. A., Rudd, P. M. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 17, 1344-1356 (2007).
23. Saito, S., Murayama, Y., Pan, Y., Taima, T., Fujimura, T., Murayama, K. Haptoglobin-beta chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer. Int J Cancer 123, 633-640 (2008).
24. Nakano, M., Nakagawa, T., Ito, T., Kitada, T., Hijioka, T., Kasahara, A., Tajiri, M., Wada, Y., Taniquchi, N., Miyoshi, E. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 122, 2301-2309 (2008).
25. Chen, C. B., Su, Y. C., Huang, T. T., Ho, H. C., Chang, Y. T., Tung, Y. T., Lee, W. C. Differentially expressed serum haptoglobin alpha chain isoforms with potential application for diagnosis of head and neck cancer. Clin Chim Acta 398, 48-52 (2008).
26. Huang, H. L., Stasyk, T., Morandell, S., Dieplinger, H., Falkensammer, G., Griesmacher, A., Mogg, M., Schreiber, M., Feuerstein, I., Huck, C. W., Stecher, G., Bonn, G. K., Huber, L. A. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 27, 1641-1650 (2006).
27. Helfman, D. M., Kim, E. J., Lukanidin, E., Grigorian, M. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 92, 1955-1958 (2005).
28. Ambartsumian, N., Klingelhöfer, J., Grigorian, M., Christensen, C., Kriajevska, M., Tulchinsky, E., Georgiev, G., Berezin, V., Bock, E., Rygaard, J., Cao, R., Cao, Y., Lukanidin, E. The metastasis-associated Mtsl(S100A4) protein could act as an angiogenic factor. Oncogene 20, 4685-4695 (2001).
29. Belot, N., Pochet, R., Heizmann, C. W., Kiss, R., Decaestecker, C. Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the organization of their actin cytoskeleton. Biochim Biophys Acta 1600, 74-83 (2002).
30. Schmidt-Hansen, B., Ornås, D., Grigorian, M., Klingelhöfer, J., Tulchinsky, E., Lukanidin, E., Ambartsumian, N. Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 23, 5487-5495 (2004).
31. Grigorian, M., Andresen, S., Tulchinsky, E., Kriajevska, M., Carlberg, C., Kruse, C., Cohn, M., Ambartsumian, N., Christensen, A., Selivanova, G., Lukanidin, E. Tumor suppressor p53 protein is a new target for the metastasis associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem 276, 22699-22708 (2001).
32. Grum-Schwensen, B., Klingelhofer, J., Berg, C. H., El-Naaman, C., Grigorian, M., Lukanidin, E., Ambartsumian, N. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res 65, 3772-3780 (2005).